PT - JOURNAL ARTICLE AU - TILMAN TODENHÖFER AU - JÖRG HENNENLOTTER AU - SUSAN FEYERABEND AU - STEFAN AUFDERKLAMM AU - JOHANNES MISCHINGER AU - URSULA KÜHS AU - VALENTINA GERBER AU - JASMIN FETISCH AU - DAVID SCHILLING AU - SIEGFRIED HAUCH AU - ARNULF STENZL AU - CHRISTIAN SCHWENTNER TI - Preliminary Experience on the Use of the Adnatest® System for Detection of Circulating Tumor Cells in Prostate Cancer Patients DP - 2012 Aug 01 TA - Anticancer Research PG - 3507--3513 VI - 32 IP - 8 4099 - http://ar.iiarjournals.org/content/32/8/3507.short 4100 - http://ar.iiarjournals.org/content/32/8/3507.full SO - Anticancer Res2012 Aug 01; 32 AB - Background: The Adnatest® system combines immunomagnetic enrichment of epithelial cells with polymerase chain reaction for prostate cancer (PC)-specific transcripts for the detection circulating tumor cells (CTCs). We evaluated the Adnatest® in patients with castration-resistant PC receiving docetaxel chemotherapy. Patients and Methods: CTCs were assessed in 16 patients with castration-resistant PC before cycles one and three of chemotherapy. Furthermore, markers of stem cells and epithelial-mesenchymal transition were assessed. Treatment response was assessed by imaging and prostate-specific antigen measurements. Results: Before chemotherapy, 11 patients were Adnatest®-positive whereas five patients were Adnatest®-positive before cycle three. A positive Adnatest® correlated with radiological progression (p=0.02). Rates of disease progression in epidermal growth factor receptor (EGFR)-positive and -negative patients were 100% and 7.7% (p=0.03). Conclusion: In this preliminary study, the Adnatest® detected CTCs in a considerable proportion of patients with castration-resistant PC. First data on certain markers (EGFR and aldehyd dehydrogenase 1) encourage future studies investigating transcripts predicting treatment response.